ANTH News Alert Anthera Pharmaceuticals (ANTH) 1.48 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Anthera Pharmaceuticals (ANTH) 1.48 $ANTH

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/3jbcb9/idiopathic) has announced the addition of the "Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Boehringer Ingelheim - Amgen - GlaxoSmithKline - Merck & Co - Symphogen - Eisai - Rigel Pharmaceuticals - Immunomedics - HanAll Biopharma - PhytoHealth - Anthera Pharmaceuticals - SuppreMol - Azano Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/3jbcb9/idiopathic
IMMU: 4.41 (+0.13), ANTH: 1.48 (unch), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), RIGL: 2.22 (+0.02)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 8:12AM CST

FRO: 2.43 (-0.01), TLM: 7.84 (unch), SPHS: 0.46 (+0.02), HGSH: 4.60 (-0.06), SN: 9.91 (-0.71), NBG: 1.95 (+0.06), AXAS: 3.16 (-0.13), RVBD: 20.35 (+0.01), OPK: 9.63 (+0.21), ANTH: 1.48 (unch), ONVO: 6.84 (+0.03), KEG: 1.73 (+0.01), CALA: 22.33 (+1.16), XCO: 2.38 (-0.03), CRUS: 23.60 (unch), ARCP: 8.33 (unch)

Anthera Pharmaceuticals Licenses Japan Rights for Blisibimod to Zenyaku Kogyo Co., Ltd.
PR Newswire - Mon Dec 15, 8:00AM CST
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) announced today that Anthera and Zenyaku Kogyo Co., Ltd. of Tokyo, Japan executed an exclusive license agreement for the development and commercialization of subcutaneous blisibimod in Japan and potentially other countries throughout Asia. Anthera retains full development and commercialization rights for all other global territories including North America and the European Union. Zenyaku currently markets Rituxan(TM), an anti-CD20 antibody, in Japan where it is approved for CD20 Positive B-Cell Lymphoma, B-cell Lymphoproliferative disorder, ANCA associated vasculitis (GPA, MPA), and Pediatric Nephrotic Syndrome.
ANTH: 1.48 (unch)

Systemic Lupus Erythematosus - Pipeline Review, H2 2014
M2 - Thu Dec 11, 5:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/lhg87v/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Biogen Idec - Amgen - Sanofi - Eli Lilly and Company - GlaxoSmithKline - MedImmune - Biotest - Ablynx - Novo Nordisk - Takeda Pharmaceutical Company - Eisai - Pfizer - UCB - Celgene Corporation - XTL Biopharmaceuticals - Merck - 4SC - Harbor Therapeutics - Immunomedics - Idera Pharmaceuticals - Karo Bio - Dynavax Technologies - Hansa Medical - Immupharma - Argos Therapeutics - MacroGenics - Kineta - Xencor - SBI Biotech - Invion Limited - Anthera Pharmaceuticals - SuppreMol - NasVax - Lycera - Genosco - RedHill Biopharma - National Pharmaceutical - Resolve Therapeutics - Lead Discovery Center - Genovax - MENTRIK Biotech - Avipep Pty - AbbVie - ImmuNext - Cellular Biomedicine Group - Medsenic - Azano Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lh...emic_lupus
DVAX: 15.35 (+0.30), BIIB: 340.89 (+5.13), IMMU: 4.41 (+0.13), RDHL: 12.22 (-0.13), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), GSK: 42.85 (+0.11), ARGS: 9.65 (+0.34), NVO: 43.80 (+1.08), IDRA: 3.89 (+0.02), ANTH: 1.48 (unch), MRK: 57.46 (+0.25), CBMG: 12.98 (+0.19), CELGZ: 3.34 (-0.01)

Wegener's Granulomatosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 3:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/q4wq75/wegeners) has announced the addition of the "Wegener's Granulomatosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Wegener's Granulomatosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wegener's Granulomatosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Wegener's Granulomatosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Wegener's Granulomatosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Anthera Pharmaceuticals - Aprogen - ChemoCentryx. - Epirus Biopharmaceuticals - Panacea Biotec - Pharmapraxis - Sandoz For more information visit http://www.researchandmarkets.com/research/q4wq75/wegeners
ANTH: 1.48 (unch)

Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference
PR Newswire - Sun Nov 23, 8:30PM CST
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), announced today that Paul F. Truex, President and Chief Executive Officer, will present a corporate update at the 2014 Annual Piper Jaffray Healthcare Conference.
ANTH: 1.48 (unch)

Anthera & Patheon signs manufacturing agreement for Liprotamase Phase III Registration Trial
M2 - Fri Nov 21, 5:55AM CST
Biopharmaceutical company Anthera Pharmaceuticals (NasdaqGM:ANTH) announced on Thursday that it has entered in a manufacturing and supply agreement for Sollpura with the Patheon division of DPx Holdings BV.
ANTH: 1.48 (unch)

Anthera and Patheon Sign Manufacturing Agreement for Liprotamase Phase III Registration Trial
PR Newswire - Thu Nov 20, 10:00AM CST
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) announced today it has signed a manufacturing and supply agreement with the Patheon® division of DPx Holdings B.V. The contract provides for Patheon to support the production of the Sollpura® clinical drug product for Anthera's Phase III registration trial (SOLUTION - see below).
ANTH: 1.48 (unch)

Anthera Pharmaceuticals beats by $0.08
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 3:53PM CST

ANTH: 1.48 (unch)

Anthera Pharmaceuticals Reports 2014 Third Quarter Financial Results and Operational Update
PR Newswire - Fri Nov 14, 3:05PM CST
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the third quarter ended September 30, 2014.
ANTH: 1.48 (unch)

Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 6.49 (+0.29), PCYC: 121.84 (+1.15), CLDX: 17.08 (-0.18), INCY: 71.57 (+1.99), BIND: 5.73 (+0.06), CELG: 109.60 (+3.48), OMER: 22.09 (+0.48), VSTM: 8.30 (+0.19), GILD: 91.29 (+1.84), OGXI: 2.10 (-0.04), ANTH: 1.48 (unch), NVAX: 5.81 (+0.18)

Anthera Pharmaceuticals Announces Update on Strategic Partnership Discussions for Blisibimod
PR Newswire - Wed Oct 01, 3:00PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today confirmed it is engaged in potential partnership negotiations for blisibimod for both lupus and IgA nephropathy in territories outside the United States.
ANTH: 1.48 (unch)

4 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Oct 01, 6:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
ROIAK: 1.66 (-0.03), ANTH: 1.48 (unch), TRXC: 2.79 (+0.03), SYMX: 0.98 (-0.02)

Qiagen's Molecular Diagnostics, Global Market Show Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 1:50PM CDT
On Sep 25, we issued an updated research report on Qiagen N.V. (QGEN).
HSKA: 18.13 (+0.24), GILD: 91.29 (+1.84), ANTH: 1.48 (unch), QGEN: 23.20 (+0.09)

Genomic Health Upbeat on Strong International Performance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 2:00PM CDT
Genomic Health (GHDX) is focused on delivering revenue growth through constant investment for higher adoption of its tests across three major cancers
CBM: 21.62 (+0.37), GILD: 91.29 (+1.84), ANTH: 1.48 (unch), GHDX: 32.44 (+1.32)

Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
ARC: 9.80 (+0.12), BIDU: 230.98 (-2.18), ANTH: 1.48 (unch), AMGN: 160.67 (+3.15), ALSN: 33.94 (+0.05)

Market Maker Surveillance Report. PDLI, AT, ISNS, QLTI, SINO, ANTH, Losing Stocks With Lowest Price Friction For Wednesday, September 17th 2014
M2 - Thu Sep 18, 3:31AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4737 companies with "abnormal" market making, 2409 companies with positive Friction Factors and 2599 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Wednesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. PDL Biopharma Inc (NASDAQ DLI), ATLANTIC POWER CORP (NYSE:AT), Image Sensing Systems Inc (NASDAQ:ISNS), QLT INC (NASDAQ:QLTI), Sino-Global Shipping America Ltd (NASDAQ:SINO), Anthera Pharmaceuticals Inc (NASDAQ:ANTH). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
AT: 2.57 (-0.10), QLTI: 3.72 (+0.08), ANTH: 1.48 (unch), ISNS: 2.77 (+0.04), SINO: 1.57 (-0.04), PDLI: 7.61 (unch)

Anthera (ANTH) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 9:41AM CDT
Anthera (ANTH) Enters Oversold Territory
ANTH: 1.48 (unch)

Anthera Pharmaceuticals (ANTH) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 8:31AM CDT
Anthera Pharmaceuticals (ANTH) Sees Hammer Chart Pattern: Time to Buy?
ANTH: 1.48 (unch)

Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update
PR Newswire - Mon Jul 28, 4:40PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the second quarter ended June 30, 2014.
ANTH: 1.48 (unch)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 73

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 21

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 44

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Clear Aligner Results Depend on Discipline, Not Hype

Updated Category News Views 115

A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....

Continue Reading
University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 89

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 104

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 96

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 40

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 61

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Unlocking AI Potential: VERSES Genius™ Surpasses Competitors

Updated Category News Views 353

VERSES Genius™ Agent Sets New Benchmark in AI Performance VERSES AI Inc., a pioneer in cognitive computing, is redefining intelligent systems with its innovative Genius™ toolkit. Recent evaluations against industry-leading benchmarks highlight its significant advancements in artificial intelligence. The preliminary results regarding the "Atari 100K Challenge" showcase...

Continue Reading
MKS Instruments Achieves Loan Repricing and Adds Prepayment

Updated Category News Views 356

MKS Instruments Achieves Loan Repricing and Adds Prepayment MKS Instruments, Inc. (NASDAQ: MKSI), a prominent global leader in enabling technologies, has made a significant leap in optimizing its financial structure. Recently, the company announced it has completed the repricing of its considerable secured tranche B term loans, which amount to a staggering $2.5 billion...

Continue Reading
Incredible Growth of Cheniere Energy: A 15-Year Journey

Updated Category News Views 238

The Remarkable Performance of Cheniere Energy Cheniere Energy, known by its trading symbol LNG, has consistently outperformed the market over the past 15 years. Investors in LNG have witnessed an incredible annualized return of 35.23%, exceeding the market by 22.77%. Currently, Cheniere Energy boasts a market capitalization of $53.26 billion, marking its growth trajectory...

Continue Reading
Adhara and ioBuilders Form New Powerhouse in Blockchain Solutions

Updated Category News Views 420

Adhara and ioBuilders Unite for Blockchain Innovation Adhara and ioBuilders have merged their expertise to create a leading provider of blockchain software products tailored specifically for financial institutions. This strategic alliance has resulted in a profitable company with a robust workforce of over 120 employees, distributed across various regions including the...

Continue Reading
Legal Action Against Lineage, Inc. Following Significant Stock Drop

Updated Category News Views 227

Overview of the Situation Surrounding Lineage, Inc. In recent times, Lineage, Inc. has found itself at the heart of a significant legal controversy following a dramatic 17% drop in its stock price. Leading with this news is the announcement of a class action lawsuit against the company and some of its top executives. Legal firm Bleichmar Fonti & Auld LLP is rallying...

Continue Reading